絞り込み

16639

広告

Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice.

著者 Terasaki M , Nagashima M , Nohtomi K , Kohashi K , Tomoyasu M , Sinmura K , Nogi Y , Katayama Y , Sato K , Itoh F , Watanabe T , Hirano T
PLoS One.2013 ; 8(8):e70933.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan.

スターを付ける スターを付ける     (372view , 0users)

Full Text Sources

Medical

Miscellaneous

Molecular Biology Databases

Several recent reports have revealed that dipeptidyl peptidase (DPP)-4 inhibitors have suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe (-/-)) mice. It remains to be seen, however, whether this effect stems from increased levels of the two active incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
PMID: 23967137 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード